CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference – Yahoo Finance
Posted: November 30, 2020 at 7:01 pm
TipRanks
Dividend stocks are the Swiss army knives of the stock market.When dividend stocks go up, you make money. When they dont go up you still make money (from the dividend). Heck, even when a dividend stock goes down in price, its not all bad news, because the dividend yield (the absolute dividend amount, divided by the stock price) gets richer the more the stock falls in price.Knowing all this, wouldnt you like to own find great dividend stocks? Of course you would. Raymond James analysts have chimed in and they are recommending two high-yield dividend stocks for investors looking to find protection for their portfolio. These are stocks with a specific set of clear attributes: a dividend yield of 10% and Strong Buy ratings.Kimbell Royalty Partners (KRP)Well start with Kimbell Royalty Partners, a land investment company operating in some of the US major oil and gas producing regions: the Bakken of North Dakota, Pennsylvanias Appalachian region, the Colorado Rockies, and several formations in Texas. Kimbell owns mineral rights in more than 13 million acres across these regions, and collects royalties from over 95,000 active wells. Over 40,000 of those wells are in the Permian Basin of Texas, the famous oil formation that has, in the past decade, helped turn the US from a net importer of hydrocarbons to a net exporter.The coronavirus crisis hit Kimbell directly in the pocketbook, knocking down share prices and earnings as economic restrictions, social lockdowns, and the economic downturn all struck at production and demand. The situation has only begun to revive, with the Q3 revenues growing 44% sequentially to reach $24.3 million.Kimbell has long been a reliable dividend payer, with a twist. Where most dividend stocks keep their payouts stable, typically making just adjustment in a year, Kimbell has a history of reevaluating its dividend payment every quarter. The result is a dividend that is rarely predictable but is always affordable for the company. The last declaration, for the third quarter, was 19 cents per common share, or up 46% from the previous quarter. At that rate, the dividend yields ~10%,Covering the stock for Raymond James, analyst John Freeman noted, Despite a strong quarterly performance and a nearly 50% distribution raise in 3Q, the market continues to under appreciate the unique value proposition of Kimbell's assets, in our view. Kimbell has a best-in-class 13% base decline, exposure to every major basin and commodity, as well as a very manageable leverage profileRegarding the possible anti-hydrocarbon stance of a Biden Administration, Freeman sees little reason for worry, saying, Investors concerned about a potential Biden presidency (which appears increasingly likely) have little to fear in KRP. The company has less than ~2% of acreage on federal lands, meaning a frac ban on those properties would not have a material impact on KRP's business and might actually help them if it improved the overall supply impact."In line with these comments, Freeman rates KRP a Strong Buy, and his $9 price target implies it has room for 25% growth going forward. (To watch Freemans track record, click here)Wall Street appears to agree with Freeman, and the analyst consensus view is also a Strong Buy, based on 5 unanimous positive reviews. This stock is priced at $7.21, and its $11 average target is even more bullish than Freemans, suggesting a one-year upside of ~52%. (See KRP stock analysis on TipRanks)NexPoint Real Estate Finance (NREF)NexPoint inhabits the real estate trust niche, investing in mortgage loans on rental units, both single- and multi-family occupancy, along with self-storage units and office spaces. The company operates in the US, across major metropolitan hubs.NexPoint held its IPO in February this year, just before the coronavirus pandemic inspired an economic crisis. The offering saw 5 million shares sell, and brought in some $95 million in capital. Since then, the shares are down 13%. Earnings, however, have posted gains in each full quarter that the company has reported as a public entity, coming in at 37 cents per share in Q2 and 52 cents in Q3. The Q3 number was 30% above the forecast.The dividend here is also solid. NexPoint started out with a 22-cent per share payment in Q1, and raised it in Q2 to its current level of 40 cents per common share. This annualizes to $1.60, making the yield an impressive ~10%.Stephan Laws, 5-star analyst with Raymond James, is impressed with what he sees here. Laws writes of NexPoint, Recent investments should drive significant core earnings growth, which is reflected in the increased 4Q guidance range of $0.49-0.53 per share (up from $0.46-0.50 per share). The guidance incorporates the full quarter impact of the new 3Q investments as well as new mezz investments made in October. We are increasing our 4Q and 2021 estimates, and we have increased confidence in our forecast for a 1Q21 dividend increase, which we now forecast at $0.45 per shareFollowing these sentiments, Laws puts a Strong Buy rating on NREF. His $18 price target suggest the stock has a 9% upside potential for the year ahead. (To watch Laws track record, click here)With 2 recent Buy reviews, the analyst consensus on NREF shares is a Moderate Buy. The stocks $18 average price target matches Laws, implying 9% growth. (See NREF stock analysis on TipRanks)To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Read the rest here:
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Yahoo Finance
- 'Incredible' gene-editing result in mice inspires plans to treat premature-aging syndrome in children - Science Magazine - January 9th, 2021
- CRISPR Therapeutics Is Still Looking Strong - RealMoney - RealMoney - January 9th, 2021
- Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change - Market is Expected to Recover to Reach $1.55 Billion in 2023 - Forecast to... - January 9th, 2021
- What is the Market's View on Crispr Therapeutics AG (CRSP) Stock's Price and Volume Trends - InvestorsObserver - January 9th, 2021
- 5 questions facing gene therapy in 2021 - BioPharma Dive - January 9th, 2021
- CRISPR-based strategies in infectious disease diagnosis and therapy - DocWire News - January 9th, 2021
- Plant Breeding And CRISPR Plants Market Is Expected To Reach USD 21.78 Billion By 2027 | Top Companies- Bayer AG, KWS SAAT SE & Co. KGaA, DuPont,... - January 9th, 2021
- Where Does Crispr Therapeutics AG (CRSP) Stock Fall in the Biotechnology Field? - InvestorsObserver - January 9th, 2021
- CRISPR and CAS Gene Market 2021-2028 shooting revenue at US$ 7,603.8 Million with CRISPR Therapeutics, Mirus Bio, Caribou Biosciences, Editas... - January 9th, 2021
- The 221b Foundation Establishes Coalition to Control the Spread of COVID-19 in Nepal - Business Wire - January 9th, 2021
- Strategies and applications for CRISPRko, RNAi and beyond - SelectScience - January 9th, 2021
- TRIM26 is a critical host factor for HCV replication and contributes to host tropism - Science Advances - January 9th, 2021
- Four Predictions for the Future of Food in 2021 - The Spoon - January 9th, 2021
- Why CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics Stocks Are Sinking Today - The Motley Fool - January 2nd, 2021
- Should Crispr Therapeutics AG (CRSP) be in Your Portfolio? - InvestorsObserver - January 2nd, 2021
- Can CRISPR Save Florida Citrus? - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - January 2nd, 2021
- 2020: The year science took centre-stage - The Hindu - January 2nd, 2021
- 2020 was a tough year, but there is a silver lining - Boston Herald - January 2nd, 2021
- Pairing CRISPR with a smartphone camera, this COVID-19 test finds results in 30 minutes - FierceBiotech - December 12th, 2020
- New CRISPR-based COVID-19 test uses smartphone cameras to spot virus RNA - University of California - December 12th, 2020
- Is CRISPR Therapeutics Heading for $170? - The Motley Fool - December 12th, 2020
- Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment... - December 12th, 2020
- De-extinction: Why CRISPR gene editing might be the most revolutionary development in science ever - Genetic Literacy Project - December 12th, 2020
- How CRISPR could help us discover and treat rare cancers - ZME Science - December 12th, 2020
- ASH: CRISPR-Cas9 Gene Editing Promising in TDT, SCD - HealthDay News - December 12th, 2020
- Kevin Davies' 'Editing Humanity' explores the CRISPR revolution and the ethical dilemmas that await us - Genetic Literacy Project - December 12th, 2020
- ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more - PMLiVE - December 12th, 2020
- CiBER-seq dissects genetic networks by quantitative CRISPRi profiling of expression phenotypes - Science Magazine - December 12th, 2020
- Global $6.7 Billion CRISPR Technology Market Opportunities to 2030: Cas9 And gRNA, Design Tool, Plasmid and Vector, Other Delivery System Products -... - November 30th, 2020
- CRISPR Therapeutics AG [CRSP] Revenue clocked in at $77.40 million, up 99.57% YTD: Whats Next? - The DBT News - November 30th, 2020
- Crispr And Crispr-Associated (Cas) Genes Market trends, Forecast Analysis, Key segmentation by type and application to 2026 - Cheshire Media - November 30th, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Insights with Global Outlook 2020-2026| Caribou Biosciences, Addgene, CRISPR THERAPEUTICS... - November 30th, 2020
- CRISPR Genome Editing Market Statistics and Research Analysis Released in Latest Industry Report 2020 | Coronavirus-COVID19 Impact Analysis With Top... - November 30th, 2020
- CRISPR Genome Editing Market to Exhibit Impressive Growth of CAGR during the pe - News by aeresearch - November 30th, 2020
- Autism genes affect development of neurons and glia - Spectrum - November 30th, 2020
- CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy - Science Advances - November 20th, 2020
- Heres Why You Should Stay Invested In CRISPR Stock Despite The Recent 3x Rally - Forbes - November 20th, 2020
- CRISPR for Citrus Greening - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West - November 20th, 2020
- CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Yahoo Finance - November 20th, 2020
- Viewpoint: Farming one of the 'most inefficient industries.' The CRISPR revolution could change that - Genetic Literacy Project - November 20th, 2020
- CRISPR-edited bananas immune to killer pathogens advance toward commercialization in Africa - Genetic Literacy Project - November 20th, 2020
- CRISPR Technology Market Forecast To 2026 And COVID-19 Impact Analysis - The Think Curiouser - November 20th, 2020
- Faster, Cheaper, Easier COVID-19 Testing - Powering the New Engineer - University of Florida - November 20th, 2020
- Seeing Real-Time Biological Interactions with Graphene Transistors - Clinical OMICs News - November 20th, 2020
- Crispr Technology Market to 2026: Report on Top Company Players, Industry Insights and Overview - PRnews Leader - November 20th, 2020
- Application and Product Portfolio Analysis During the forecasted period of CRISPR Technology Market - PRnews Leader - November 20th, 2020
- CRISPR Genome Editing Market Research Report- Opportunities & Challenges With Totally Different Segments, Forecast- 2026 - The Think Curiouser - November 3rd, 2020
- Latest News 2020: CRISPR Technology Market by Coronavirus-COVID19 Impact Analysis With Top Manufacturers Analysis | Top Players: Thermo Fisher... - November 3rd, 2020
- Global CRISPR And CRISPR-Associated (Cas) Genes Market Views: Taking A Nimble Approach To Explores Huge Growth In Near Future With Eminent Players -... - November 3rd, 2020
- 3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis... - November 3rd, 2020
- The Impact of the Coronavirus on the Global CRISPR and Cas Genes Market Fact.MR Study 2020 2026 - The Cloud Tribune - November 3rd, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market: Drivers, Restraints, Opportunities, and Threats (20192025) - Eurowire - October 31st, 2020
- CRISPR Can be a Solution to Address the COVID-19 Pandemic | Roots Analysis - The Think Curiouser - October 31st, 2020
- Picking up where GMOs left off: CRISPR leads the way to 'greener' food production in the 21st century - Genetic Literacy Project - October 31st, 2020
- CRISPR is going to reshape the future of probiotic genomes: Expert - NutraIngredients-usa.com - October 29th, 2020
- Did The Underlying Business Drive CRISPR Therapeutics' (NASDAQ:CRSP) Lovely 407% Share Price Gain? - Yahoo Finance - October 29th, 2020
- CRISPR Therapeutics Stock Falls 3.5% on Q3 Results - Motley Fool - October 29th, 2020
- Plant Breeding and CRISPR Plants Market Report 2026 Focuses on Top Companies, Research Methodology, Drivers and Opportunities - Eurowire - October 29th, 2020
- CRISPR pioneer: "Science is on the ballot" in 2020 - Axios - October 28th, 2020
- Fast, cheap, accurate: Researchers pin hopes on Nobel Prize-winning CRISPR technology to detect coronavirus - USA TODAY - October 28th, 2020
- Kara Swisher and Dr. Jennifer Doudna on CRISPR and Its Possibilities - The New York Times - October 28th, 2020
- CRISPR-Cas9: The gene editing tool that has revolutionized molecular biology - McGill Tribune - October 28th, 2020
- Is CRISPR gene therapy for rare Angelman Syndrome on the horizon? - Health Europa - October 28th, 2020
- Molecular Dynamics Reveals a DNA-Induced Dynamic Switch Triggering Activation of CRISPR-Cas12a - DocWire News - October 28th, 2020
- Is CRISPR Therapeutics Really Headed to $110? - Motley Fool - October 28th, 2020
- Investing in Genomics and CRISPR - Everything You Need to Know - Securities.io - October 28th, 2020
- Pac-Man meets genetics in new DNA editing that plays like the game - SYFY WIRE - October 28th, 2020
- CRISPR Technology Market SWOT Analysis, Latest Trends, By Top Key Players- Thermo Fisher Scientific Merck KGaA GenScript Integrated DNA Technologies... - October 28th, 2020
- Women in Science: Thoughts on the 2020 Nobel Prize in Chemistry - Loma Beat - October 28th, 2020
- CRISPR Technology Market Will Generate New Growth Opportunities in the upcoming year - Aerospace Journal - October 28th, 2020
- CRISPR and Cas Genes Market Insight | Strategic Industry Evolutionary Analysis Focus on Leading Key Players and Revenue Growth Analysis by Forecast To... - October 28th, 2020
- CRISPR Technology Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact | Top Players:... - October 28th, 2020
- 'CRISPR and Coronavirus': Hear From Nobel Winner Jennifer Doudna - UC Davis - October 22nd, 2020
- UPDATED: CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies marred by the death of a patient - Endpoints News - October 22nd, 2020
- Intellia to kick-start first single-course 'curative' CRISPR shot, as it hopes to beat rivals Alnylam, Ionis and Pfizer - FierceBiotech - October 22nd, 2020
- CRISPR has brought pig-to-human organ transplants to the cusp of reality - Genetic Literacy Project - October 22nd, 2020
- CRISPR Cas9 Industry Market Overview, Environmental Analysis and Forecast to 2025 - Express Journal - October 22nd, 2020
- Advances and concerns raised by Crispr-Cas 9, the genetic scissors - Pledge Times - October 22nd, 2020
- What is CRISPR, the gene editing technology that won the Chemistry Nobel prize? - Grain Central - October 22nd, 2020
- CRISPR Can be a Solution to Address the COVID-19 Pandemic | Roots Analysis - Eurowire - October 22nd, 2020